CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 2.31% for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2019-08-14
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2019-03-31 was 2.53%, a 3.80% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2018-09-30 was 2.75%, a 53.63% increase year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2018-03-31 was 2.63%, a 36.27% increase year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2017-09-30 was 1.79%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2013 was 0.34%, a 25.93% increase from fiscal 2012.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2012 was 0.27%, a 70.00% decline from fiscal 2011.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2011 was 0.90%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2019-06-30 | 2.31% 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | 2.53% 10-Q · filed 2019-05-13 | |||
| 2018-09-30 | 2.75% 10-Q · filed 2018-11-14 | 2.63% 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | 2.63% 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | 2.63% 10-Q · filed 2019-05-13 | |||
| 2017-09-30 | 1.79% 10-Q · filed 2018-11-14 | 1.77% 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | 1.77% 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | 1.93% 10-Q · filed 2018-05-15 | |||
| 2016-09-30 | 1.14% 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | 1.25% 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | 1.25% 10-Q · filed 2017-05-10 | |||
| 2014-03-31 | 1.51% 10-Q · filed 2014-05-15 | |||
| 2013-12-31 | 0.34% 10-K · filed 2014-03-31 | |||
| 2013-09-30 | 0.34% 10-Q/A · filed 2014-03-04 | |||
| 2013-06-30 | 0.81% 10-Q/A · filed 2014-03-04 | |||
| 2013-03-31 | 0.81% 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | 0.27% 10-K · filed 2014-03-31 | |||
| 2012-09-30 | 0.27% 10-Q/A · filed 2014-03-04 | |||
| 2012-06-30 | 0.27% 10-Q/A · filed 2014-03-04 | |||
| 2012-03-31 | 0.86% 10-Q/A · filed 2014-03-04 | |||
| 2011-12-31 | 0.90% 10-K/A · filed 2014-03-04 | |||
| 2011-09-30 | 1.02% 10-Q/A · filed 2013-03-27 | |||
| 2011-06-30 | 1.75% 10-Q/A · filed 2012-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |